1. Home
  2. LYRA vs SWAG Comparison

LYRA vs SWAG Comparison

Compare LYRA & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • SWAG
  • Stock Information
  • Founded
  • LYRA 2005
  • SWAG 1994
  • Country
  • LYRA United States
  • SWAG United States
  • Employees
  • LYRA N/A
  • SWAG N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • SWAG Advertising
  • Sector
  • LYRA Health Care
  • SWAG Consumer Discretionary
  • Exchange
  • LYRA Nasdaq
  • SWAG Nasdaq
  • Market Cap
  • LYRA 13.5M
  • SWAG 14.7M
  • IPO Year
  • LYRA 2020
  • SWAG 2021
  • Fundamental
  • Price
  • LYRA $0.19
  • SWAG $0.83
  • Analyst Decision
  • LYRA Buy
  • SWAG
  • Analyst Count
  • LYRA 5
  • SWAG 0
  • Target Price
  • LYRA $4.50
  • SWAG N/A
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • SWAG 68.4K
  • Earning Date
  • LYRA 11-12-2024
  • SWAG 01-28-2025
  • Dividend Yield
  • LYRA N/A
  • SWAG N/A
  • EPS Growth
  • LYRA N/A
  • SWAG N/A
  • EPS
  • LYRA N/A
  • SWAG 0.00
  • Revenue
  • LYRA $1,471,000.00
  • SWAG $75,893,871.00
  • Revenue This Year
  • LYRA N/A
  • SWAG $11.55
  • Revenue Next Year
  • LYRA N/A
  • SWAG N/A
  • P/E Ratio
  • LYRA N/A
  • SWAG $440.42
  • Revenue Growth
  • LYRA 3.37
  • SWAG 28.74
  • 52 Week Low
  • LYRA $0.16
  • SWAG $0.73
  • 52 Week High
  • LYRA $6.79
  • SWAG $1.69
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 46.20
  • SWAG 41.80
  • Support Level
  • LYRA $0.18
  • SWAG $0.75
  • Resistance Level
  • LYRA $0.22
  • SWAG $1.01
  • Average True Range (ATR)
  • LYRA 0.02
  • SWAG 0.07
  • MACD
  • LYRA -0.00
  • SWAG -0.00
  • Stochastic Oscillator
  • LYRA 16.31
  • SWAG 45.07

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, It offer its clients with custom sourcing capabilities which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, and event assets, order and inventory management, and designing and hosting online retail popup shops. The company purchases products and branding through various third-party manufacturers and decorators and resells the finished goods to customers.

Share on Social Networks: